Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Subscribe To Our Newsletter & Stay Updated
